Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy

The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study

(2010) Patric J. Jansson et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Membrane Transport and Intracellular Sequestration of Novel Thiosemicarbazone Chelators for the Treatment of Cancer

(2010) A. M. Merlot et al.   MOLECULAR PHARMACOLOGY

Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): No overt alteration in phenotype

(2009) Yohan Suryo Rahmanto et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors

(2009) Yu Yu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells

(2008) Egarit Noulsri et al.   AMERICAN JOURNAL OF HEMATOLOGY

The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: A comparison with desferrioxamine

(2008) Marjan Gharagozloo et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas

(2008) Steven Attia et al.   INVESTIGATIONAL NEW DRUGS

Part II: Liver function in oncology: towards safer chemotherapy use

(2008) Kathryn M Field et al.   LANCET ONCOLOGY

Part I: Liver function in oncology: biochemistry and beyond

(2008) Kathryn M Field et al.   LANCET ONCOLOGY

Clinical application of deferasirox: Practical patient management

(2007) Elliott Vichinsky   AMERICAN JOURNAL OF HEMATOLOGY

A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

(2007) Judith E. Karp et al.   LEUKEMIA RESEARCH